Novel mutations expand the clinical spectrum of DYNC1H1-associated spinal muscular atrophy

GLOSSEY

ADHD = attention deficit hyperactivity disorder; BICD2 = bicaudal D homolog 2 (Drosophila); CBCL = Child Behavior Checklist; DYNC1H1 = dynein, cytoplasmic 1, heavy chain 1; LED = lower extremity predominance; Loa = legs at odd angles; MCD = malformation of cortical development; SMA = spinal muscular atrophy.

Autosomal dominant congenital spinal muscular atrophy with lower extremity predominance (SMA-LED) has been described for decades1–4 and is characterized by congenital or early childhood onset, motor neuron degeneration, and lower limb–predominant weakness. Mutations in dynein, cytoplasmic 1, heavy chain 1 (DYNC1H1) (OMIM #158600) and bicaudal D homolog

*These authors contributed equally to this work.
†These authors contributed equally to this work.

From the Dubowitz Neuromuscular Center (M.S., M.C., S.R., A.Y.M., C.S., R.P., F.M.) and MRC Center for Neuromuscular Diseases (F.M.), UCL Institute of Child Health, London, UK; MRC Center for Neuromuscular Diseases (A.M.R., M.M.R.), UCL Institute of Neurology, Queen Square, London, UK; Neuromuscular Division (M.B.H., A.M.C., M.T.A.-L.), Department of Neurology, Washington University School of Medicine, St. Louis, MO; Research Center for Genetic Medicine (S.C.), Children’s National Medical Center, Washington, DC; Galdakao-Umansolo Hospital (A.M.A., A.R.S.), Department of Neurology, Barrio Labega s/n, Usansolo, Vizcaya, Spain; St George’s NHS Health Care Trust (S.M., P.F., I.H.), London, UK; Department of Paediatric Neurology (A.K.), University Children’s Hospital, Zurich, Switzerland; Department of Pediatrics (M.Y.), University of Colorado Denver; Department of Neurology (M.D.V., W.C.G.O.-P., F.B.), Academic Medical Center, University of Amsterdam, the Netherlands; Human Genetics Unit (C.M.), Ninewells Hospital, Dundee; Center for Inherited Neuromuscular Diseases (C.S.), PJAH Orthopaedic NHS Foundation Trust, Oswestry; School of Life Sciences (M.H.), University of Sussex, John Maynard Smith Building, Brighton; Radiology Department (W.K.C.) and Neuropathology Department (M.P.), Great Ormond Street Hospital, London, UK; Paediatric Neurology Unit (E.M.), Policlinico Gemelli, Rome, Italy; Department of Neurology (R.H.B.), Cedars Sinai Medical Center, Los Angeles, CA; Department of Developmental Neurobiology (J.P.T.), St. Jude Children’s Research Hospital, Memphis, TN; Neurology Department (M.B.), University of Miami Miller School of Medicine, Fl.; and Department of Neurology (J.N., C.G.E.L.d.G.), Royal Preston Hospital, UK.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

© 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Three tail domain mutations in the mouse homolog of DYNC1H1 have been described: “legs at odd angles” (Loa), “crawling” (Cra1), and “sprawling” (Swl).16,17 all sharing motor and sensory deficits and the Loa mice demonstrating cortical migration defects.18 Phenotypic differences among these models and the emerging diversity of reported patients, suggests that the human DYNC1H1 clinical spectrum extends beyond SMA-LED. This report describes 30 affected patients from 16 families with mutations in DYNC1H1. Although they are predominantly affected by SMA-LED, some have severe generalized arthrogryposis and one-third have cognitive impairment, which is frequently associated with MCDs.

RESULTS Subjects and mutational spectrum. Thirty subjects with DYNC1H1 mutations were included in this study (table 1), 25 of whom came from 11 different families and 5 of whom were apparently sporadic. Thirteen different DYNC1H1 mutations were found: 10 are novel, with 8 located in the tail domain and 2 in the motor domain (table 1, figure 1). Twenty-three cases demonstrated autosomal dominant inheritance with appropriate variant segregation. De novo heterozygous mutations were confirmed in 2 sporadic subjects. Four families carried the same p.Val612Met mutation, but haplotype analysis showed that the p.Val612Met variant stems from a founder mutation or represents a mutational hotspot, 3 microsatellites flanking DYNC1H1 (D14S985, D14S1051, and D14S1007) and spanning 10.1 cm were genotyped in all carriers of this variant. Rare and novel polymorphisms segregating with the p.Val612Met variant in US4 were identified from exome sequencing data and genotyped in other pedigrees.

Clinical investigations. Case-notes review. Medical records were reviewed for all affected individuals, and available subjects were re-examined. The patients followed at the Dubowitz Neuromuscular Center who presented with cognitive impairment and/or behavioral difficulties completed the Child Behavior Checklist (CBCL) and Conners 3 for parents questionnaires.24,25 Subjects with Conners t scores in the abnormal range (t < 65) on the hyperactivity and/or inattention indexes were categorized as meeting criteria for attention deficit hyperactivity disorder (ADHD). The CBCL is a parent-report measure, including scales indicating the presence of externalizing symptoms (including hyperactivity). Subjects with a cutoff score of 19 were considered as having externalizing symptoms.

Ancillary clinical testing. Nerve conduction studies and EMG were conducted in 23 subjects. Muscle biopsies had been performed in 13 patients, with frozen sections stained according to standard procedures.26 MRI of the lower limbs was performed in 9 subjects using conventional T1-weighted spin-echo sequences according to reported methodology.27 Noncontrast images were obtained from the pelvis, thighs, and legs. Fifteen patients had undergone brain MRI.

METHODS Subjects. Patients with non–length-dependent motor neuropathies predominantly affecting the lower limbs were identified at participating neuromuscular centers and referred for DYNC1H1 sequencing.

Standard protocol approvals, registrations, and patient consents. Informed consent for clinical study and molecular genetic analysis was obtained from patients or their parents/legal guardians at all referring institutions. Local ethics committees approved this study.

Molecular genetic analysis. DYNC1H1 sequencing. Most subjects underwent Sanger sequencing of the tail domain of DYNC1H1 (exons 5–15) at either the Institute of Neurology, UCL, or at Washington University in St. Louis. Twelve primer pairs were used to amplify exons and flanking intronic sequences and were sequenced bidirectionally (primer details available on request). Five pedigrees (families UK4, 8, 9, US3, and NL1) had DYNC1H1 mutations identified from whole-exome analysis followed by Sanger sequencing validation.

Bioinformatics. All identified variants were referenced to NM_001376.4 using HGVS (Human Genome Variation Society) nomenclature (http://www.genenames.org) and compared against the National Heart, Lung, and Blood Institute Exome Sequencing Project, Exome Variant Server (http://evs.gs.washington.edu/EVS/). In silico analyses of mutations were performed using PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/),29 SIFT (http://sift.jcvi.org),30 PROVEAN (http://provean.jcvi.org),31 MutationTaster (http://www.mutationtaster.org),22 and MutationAssessor (http://mutationassessor.org)31 (table e-1 on the Neurology® Web site at Neurology.org).

Haplotype analysis. To determine whether the p.Val612Met mutation stems from a founder mutation or represents a mutational hotspot, 3 microsatellites flanking DYNC1H1 (D14S985, D14S1051, and D14S1007) and spanning 10.1 cm were genotyped in all carriers of this variant. Rare and novel polymorphisms segregating with the p.Val612Met variant in US4 were identified from exome sequencing data and genotyped in other pedigrees.
<table>
<thead>
<tr>
<th>Patient/ family</th>
<th>Mutation and inheritance</th>
<th>Age at onset, y</th>
<th>Presentation</th>
<th>Age at examination, y</th>
<th>Maximum motor abilities</th>
<th>Muscle atrophy</th>
<th>Muscle weakness</th>
<th>DTR</th>
<th>Joint contractures</th>
<th>Cognitive impairment</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK1a</td>
<td>AD heterozygous, p.R399G, exon 8</td>
<td>Adult</td>
<td>Weakness LL</td>
<td>40s</td>
<td>WI</td>
<td>Dist LL</td>
<td>Dist LL</td>
<td>+ UL, ±LL</td>
<td>TAs</td>
<td>ND</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>AD homozygous, p.R399G, exon 8</td>
<td>Birth</td>
<td>Arthrogryposis LL &gt; UL, axial hypotonia</td>
<td>9.5</td>
<td>SI, SWS, crawling</td>
<td>Dist LL</td>
<td>Prox LL</td>
<td>+ UL, ±LL</td>
<td>Hips, knees, ITBs</td>
<td>Moderate and ADHD</td>
<td>Valgus feet</td>
</tr>
<tr>
<td>UK2a</td>
<td>De novo heterozygous, p.R264Q, exon 5</td>
<td>Birth</td>
<td>Arthrogryposis LL &gt; UL</td>
<td>10</td>
<td>SI, SWS</td>
<td>Dist LL</td>
<td>LL prox &gt; dist</td>
<td>+ UL, ±LL</td>
<td>Hips, knees, ITBs, TAs</td>
<td>Mild and ADHD</td>
<td>Valgus feet</td>
</tr>
<tr>
<td>UK3</td>
<td>AD heterozygous, p.Y970C, exon 11</td>
<td>&lt;2</td>
<td>MD, abnormal gait</td>
<td>5</td>
<td>WI, WG</td>
<td>LL dist &gt; prox</td>
<td>LL prox</td>
<td>+ UL, ±LL</td>
<td>Hips, knees, TAs</td>
<td>Mild and ADHD</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>AD heterozygous, p.Y970C, exon 11</td>
<td>&lt;2</td>
<td>MD, abnormal gait</td>
<td>9</td>
<td>WI, NRCS</td>
<td>Dist LL and UL</td>
<td>LL prox &gt; dist</td>
<td>+ UL, ±LL</td>
<td>End of range hips</td>
<td>Mild and ADHD</td>
<td>—</td>
</tr>
<tr>
<td>UK4a</td>
<td>AD heterozygous, p.R598C, exon 8</td>
<td>Childhood</td>
<td>WG</td>
<td>40s</td>
<td>WI</td>
<td>LL dist &gt; prox</td>
<td>LL</td>
<td>ND</td>
<td>ND</td>
<td>No</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>AD heterozygous, p.R598C, exon 8</td>
<td>Birth</td>
<td>Talipes</td>
<td>16</td>
<td>WI, best with KAFOs</td>
<td>LL dist &gt; prox</td>
<td>LL prox &gt; dist</td>
<td>+ UL, ±LL</td>
<td>Hips, knees, ITBs</td>
<td>No</td>
<td>Valgus feet</td>
</tr>
<tr>
<td>UK5a</td>
<td>Heterozygous, p.M581L, exon 8</td>
<td>Birth</td>
<td>Talipes</td>
<td>8</td>
<td>WI, WG, NRCS</td>
<td>LL dist &gt; prox</td>
<td>Prox LL</td>
<td>+ UL, ±LL</td>
<td>Knees, TAs</td>
<td>No</td>
<td>Valgus feet</td>
</tr>
<tr>
<td>UK6a</td>
<td>AD heterozygous, p.W673C, exon 8</td>
<td>Utero</td>
<td>CHD, talipes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5</td>
<td>WI, WG, using AFOs</td>
<td>LL</td>
<td>LL</td>
<td>−LL</td>
<td>Hips, knees, TAs</td>
<td>No</td>
<td>—</td>
</tr>
<tr>
<td>UK7a</td>
<td>AD heterozygous, p.E603V, exon 8</td>
<td>Utero</td>
<td>Talipes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>3.5</td>
<td>WI using AFOs</td>
<td>LL dist = prox</td>
<td>LL</td>
<td>+ LL</td>
<td>Hips, TAs</td>
<td>No</td>
<td>—</td>
</tr>
<tr>
<td>UK8a</td>
<td>ND</td>
<td>Birth</td>
<td>Talipes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>6</td>
<td>WI</td>
<td>LL dist = prox</td>
<td>ND</td>
<td>+ LL</td>
<td>TAs</td>
<td>No</td>
<td>—</td>
</tr>
<tr>
<td>UK9a</td>
<td>De novo heterozygous, p.R1603T, exon 23</td>
<td>Utero</td>
<td>Talipes and leg contractures</td>
<td>2.5</td>
<td>CC, SS</td>
<td>LL dist</td>
<td>LL prox = dist</td>
<td>−LL</td>
<td>Knees, TAs</td>
<td>ND, neurodevelopmental delay</td>
<td>Epilepsy, exotropia, valgus feet</td>
</tr>
<tr>
<td></td>
<td>Heterozygous, p.D338N, exon 6</td>
<td>Utero</td>
<td>Talipes&lt;sup&gt;b&lt;/sup&gt;, arthrogryposis LL = UL, need ventilation</td>
<td>3</td>
<td>SI</td>
<td>UL = LL dist</td>
<td>LL &gt; UL, bulbar</td>
<td>ND</td>
<td>Hips, knees, and adducted thumbs</td>
<td>ND, speech delay</td>
<td>Nissen + PEG at 1 y</td>
</tr>
<tr>
<td>Patient/family</td>
<td>Mutation and inheritance</td>
<td>Age at onset, y</td>
<td>Presentation</td>
<td>Age at examination, y</td>
<td>Maximum motor abilities</td>
<td>Muscle atrophy</td>
<td>Muscle weakness</td>
<td>DTR</td>
<td>Joint contractures</td>
<td>Cognitive impairment</td>
<td>Other</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>-------------------------</td>
<td>----------------</td>
<td>----------------</td>
<td>-----</td>
<td>-------------------</td>
<td>-------------------</td>
<td>-------</td>
</tr>
<tr>
<td>SP1 I</td>
<td>AD heterozygous, p.V612M, exon 8</td>
<td>Late 40s</td>
<td>Right leg limp</td>
<td>80s</td>
<td>WI</td>
<td>LL dist = prox</td>
<td>Prox LL</td>
<td>+ LL</td>
<td>No</td>
<td>No</td>
<td>PC</td>
</tr>
<tr>
<td>II</td>
<td>AD heterozygous, p.V612M, exon 8</td>
<td>Childhood</td>
<td>GMD</td>
<td>50s</td>
<td>WI</td>
<td>No</td>
<td>Prox LL</td>
<td>+ LL</td>
<td>No</td>
<td>No</td>
<td>PC</td>
</tr>
<tr>
<td>III</td>
<td>AD heterozygous, p.V612M, exon 8</td>
<td>20s</td>
<td>DCS</td>
<td>50s</td>
<td>WI</td>
<td>Prox LL</td>
<td>LL prox &gt; dist</td>
<td>+ LL</td>
<td>No</td>
<td>No</td>
<td>PC</td>
</tr>
<tr>
<td>IV</td>
<td>AD heterozygous, p.V612M, exon 8</td>
<td>20s</td>
<td>Leg cramps, quad fasciculations</td>
<td>22</td>
<td>WI</td>
<td>No</td>
<td>No</td>
<td>+ LL</td>
<td>No</td>
<td>No</td>
<td>No, ADHD on methilphenidate</td>
</tr>
<tr>
<td>V</td>
<td>AD heterozygous, p.V612M, exon 8</td>
<td>Childhood</td>
<td>GMD</td>
<td>37</td>
<td>WI</td>
<td>LL dist = prox</td>
<td>Prox LL</td>
<td>+ LL</td>
<td>No</td>
<td>No</td>
<td>PP</td>
</tr>
<tr>
<td>US1 I</td>
<td>AD heterozygous, p.I584L, exon 8</td>
<td>&lt;2</td>
<td>MD</td>
<td>10</td>
<td>WI</td>
<td>LL prox &gt; dist</td>
<td>LL prox &gt; dist</td>
<td>+ LL</td>
<td>No</td>
<td>Mild Exotropia</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>AD heterozygous, p.I584L, exon 8</td>
<td>&lt;2</td>
<td>MD</td>
<td>9</td>
<td>WI</td>
<td>LL dist = prox</td>
<td>LL prox = dist</td>
<td>+ LL</td>
<td>No</td>
<td>Mild Hydroceph, NS</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>ND</td>
<td>1.5</td>
<td>Cruising</td>
<td>LL dist = prox</td>
<td>LL prox = dist</td>
<td>+ LL</td>
<td>No</td>
<td>ND</td>
<td>PP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US2 I</td>
<td>Heterozygous, p.V612M, exon 8</td>
<td>Birth</td>
<td>Talipes</td>
<td>15</td>
<td>WI, WG, best with cane</td>
<td>LL dist = prox</td>
<td>LL prox &gt; dist</td>
<td>- Knees</td>
<td>No</td>
<td>Mild Exotropia, CHD</td>
<td></td>
</tr>
<tr>
<td>US3 I</td>
<td>AD heterozygous, p.V612M, exon 8</td>
<td>25</td>
<td>Weakness LL prox</td>
<td>56</td>
<td>WI</td>
<td>No</td>
<td>LL prox &gt; dist</td>
<td>+ + + LL</td>
<td>No</td>
<td>No</td>
<td>—</td>
</tr>
<tr>
<td>II</td>
<td>AD heterozygous, p.V612M, exon 8</td>
<td>32</td>
<td>Weakness LL prox</td>
<td>62</td>
<td>WI</td>
<td>No</td>
<td>LL prox = dist</td>
<td>+ + + LL</td>
<td>No</td>
<td>No</td>
<td>—</td>
</tr>
<tr>
<td>Sw1 I</td>
<td>AD heterozygous, p.V612M, exon 8</td>
<td>Birth</td>
<td>Externally rotated and small feet</td>
<td>1</td>
<td>WI, on toes</td>
<td>No</td>
<td>LL mild prox</td>
<td>+ +</td>
<td>No</td>
<td>No</td>
<td>—</td>
</tr>
<tr>
<td>II</td>
<td>AD heterozygous, p.V612M, exon 8</td>
<td>&lt;1</td>
<td>CHD</td>
<td>30s</td>
<td>WI, never run/ hop</td>
<td>No</td>
<td>LL prox &gt; dist, axial</td>
<td>+ +</td>
<td>TAs</td>
<td>No</td>
<td>—</td>
</tr>
<tr>
<td>Sw2 I</td>
<td>AD heterozygous, p.R598L, exon 8</td>
<td>&lt;1</td>
<td>MD</td>
<td>11</td>
<td>WI, WG</td>
<td>LL dist</td>
<td>LL prox &gt; dist</td>
<td>- Knees, ± TA</td>
<td>TAs</td>
<td>No</td>
<td>Equinovarus feet</td>
</tr>
<tr>
<td>II</td>
<td>AD heterozygous, p.R598L, exon 8</td>
<td>Childhood</td>
<td>GMD</td>
<td>45</td>
<td>WI</td>
<td>LL dist, asymmetric</td>
<td>LL prox</td>
<td>+ LL</td>
<td>TAs</td>
<td>No</td>
<td>PC</td>
</tr>
</tbody>
</table>
Table 1 Continued

<table>
<thead>
<tr>
<th>Patient/ family</th>
<th>Mutation and inheritance</th>
<th>Age at onset, y</th>
<th>Age at examination, y</th>
<th>Maximum motor abilities</th>
<th>Muscle atrophy</th>
<th>Muscle weakness</th>
<th>Cognitive impairment</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>NL1+</td>
<td>AD heterozygous, P.E2691K, ecen</td>
<td>5</td>
<td>WI</td>
<td>LL dist</td>
<td>LL dist</td>
<td>Weakness LL prox</td>
<td>Mild</td>
<td>PP</td>
</tr>
<tr>
<td></td>
<td>AD heterozygous, P.E2691K, ecen</td>
<td>&gt; 20s</td>
<td>WI</td>
<td>LL dist</td>
<td>LL dist</td>
<td>Weakness LL prox</td>
<td>Mild</td>
<td>PP</td>
</tr>
<tr>
<td></td>
<td>AD heterozygous, P.E2691K, ecen</td>
<td>20s</td>
<td>WI</td>
<td>LL dist</td>
<td>LL dist</td>
<td>Weakness LL prox</td>
<td>Mild</td>
<td>PP</td>
</tr>
</tbody>
</table>

Abbreviations: AD = autosomal dominant; ADHD = attention deficit hyperactivity disorder; AFO = ankle-foot orthosis; CC = commando crawling; CHD = congenital heart disease; DCS = difficulty climbing stairs; DTR = deep tendon reflexes; GMD = gross motor difficulties; hydroceph = hydrocephalus; ITB = iliotibial band; KAFO = knee-ankle-foot orthosis; MDS = motor delay; ND = not done; Nissen fundoplication procedure; PEG = percutaneous endoscopic gastrostomy; PF = pes cavus; PES = pes planus; PC = pes cavus; PES = pes planus; poly = polydactyly; SI = sit independently; SS = sit with support; TA = Achilles tendon; UL = upper limbs; WI = waddling gait; WII = walks independently.

Symbols: = present but weak; ± = present normal; ++ = brisk; ++ + = hyperactive; ** = absent; # = already detected at the fetal ultrasound scan at 20 weeks of gestation.

The distribution of DYNC1H1 mutations from this study and the literature is shown in figure 1.

Clinical spectrum of DYNC1H1 mutations. To better characterize the phenotypic spectrum caused by DYNC1H1 mutations, clinical data for all affected individuals were obtained (table 1). Symptom onset ranged from in utero to late adulthood. Thirty-seven percent presented at birth with lower limb malformations, including 4 severe patients (UK1-II, UK2-I, UK8-I, and UK9-I) who presented at birth with congenital arthrogryposis affecting both the upper and lower limbs, with predominant lower limb involvement associated with respiratory and feeding difficulties in one case; 23% presented in infancy (motor delays and abnormal gait), and 17% in childhood (gross motor difficulties or frequent falls). One-fifth of subjects presented in adulthood with a variable degree of lower limb weakness. In family UK1-II with a codominant homozygous tail domain mutation (p.Arg399Gly), the heterozygous father showed lower limb denervation and positive family history for cognitive impairment, while the heterozygous mother only had positive family history for neurodevelopmental delay. Of note, the homozygous child of this couple was one of the most severely affected subjects: born with arthrogryposis, she never achieved independent ambulation and had mental retardation in association with ADHD. Four severely affected patients never walked. The remaining subjects achieved independent but abnormal ambulation, ranging from waddling to frequent falls and difficulties with stairs, and required bracing in some cases. None of the subjects lost ambulation with aging.

As in the original description of SMA-LED, most subjects showed more pronounced involvement of the lower limbs in comparison to the upper limbs. Although distal muscles were atrophic, weakness in proximal leg muscles predominated (figure 2). Muscle function was largely preserved in the arms and hands. Minimal distal hand weakness could be detected in a minority, but only the most affected subjects showed compromised hand function (UK2-I had tremor, grasp, and fine motor difficulties with wasting of the thenar eminence; UK9-I had tremor and adducted thumbs). Deep tendon reflexes were present in the upper limbs and diminished or absent in the lower limbs. Foot deformities (equinovarus or valgus feet and pes cavus or planus) and joint contractures (hips, knees, and ankles) were each detected in approximately half of the subjects.

Electrophysiology. Nerve conduction studies and EMG were performed in 23 subjects and showed a motor neuropathy/neuronopathy without sensory involvement in all cases. All 4 subjects who had upper limb EMG showed neurogenic changes there as well.
DYNC1H1 is a large gene encoding the heavy chain 1 of the cytoplasmic dynein protein complex, a ubiquitously expressed multisubunit molecular motor involved in retrograde axonal transport, cell migration, nucleokinesis, Golgi localization, and autophagy. The dynein complex consists of 2 heavy chains (dark blue), 2 intermediate chains (dark green), 4 light intermediate chains (light green), and a number of light chains (light blue). The tail domain, located in the N-terminus, is required for heavy chain dimerization. The dynein heavy chain motor domain (C-terminus) possesses adenosine triphosphate hydrolase activity and is required for movement along microtubules. This figure shows the position of all mutations described in this report and in the published literature. The mutations identified in this study to cause both SMA-LED and MCD can be seen to span the entire length of the protein. The cluster of mutations in the dimerization domain may be explained by the selective screening for mutations in this domain. *Novel mutation. CMT2 = Charcot-Marie-Tooth disease type 2; LD = learning disability with cognitive/behavioral impairment; MCD = malformation of cortical development; SMA-LED = spinal muscular atrophy with lower extremity predominance.

and 2 were also found to have neurogenic changes in the bulbar muscles (table e-3).

**Muscle histology.** Thirteen subjects had undergone muscle biopsy, usually of a quadriceps muscle. Most biopsies showed chronic denervation but other heterogeneous features were also noted in some muscles (table e-3). Two previously reported cases showed type 2 muscle fiber predominance. Two biopsies from 2 members of family UK1 (carrying respectively a heterozygous and a homozygous p.Arg399Gly mutation) were initially considered compatible with a myopathic process because of the presence of core-like areas. Finally, in family US3, the presence of increased internal nuclei and rimmed vacuoles was also reported.

**Muscle MRI.** MRI of the lower limb muscles in 9 subjects (6 children and 3 adults) demonstrated a common pattern of involvement. In the thigh, the quadriceps muscles showed diffuse involvement with selective sparing and relative hypertrophy of the adductor magnus and/or longus and of the semitendinosus muscles.

In the lower leg, there was diffuse involvement with relative sparing of the anterior-medial muscles. In a few subjects with more mild lower leg involvement, the anterior-medial compartment appeared preserved compared with the posterior compartment (figure 3). One of our cases (UK4-II) was described before mutations in DYNC1H1 were found in SMA-LED.4

**CNS involvement and brain imaging.** Ten subjects had some degree of cognitive impairment. Among the 5 subjects with mild to moderate cognitive impairment followed at the Dubowitz Neuromuscular Center, an association with ADHD traits, according to the scores in the CBCL and Conners 3 questionnaires, was documented in 4 subjects, one of whom was already treated with methylphenidate. Another 5 subjects had mild cognitive impairment and one subject had a diagnosis of ADHD, treated with methylphenidate, with normal cognitive ability (table 1).

MRI of the brain showed similar abnormalities in 4 of 15 subjects. Each subject showed a common pattern of brain malformation resembling polymicrogyria,
characterized by cortical nodularity or gyral overconvolutions (figure 4, table e-3), best seen in the frontal and perisylvian cortex. The sylvian fissures extended posteriorly as a parietal cleft in 3 subjects (unilateral in 1 and bilateral in 2). All subjects with abnormal brain MRI had cognitive impairment or neurodevelopmental delay and 3 had ADHD traits.

DISCUSSION Autosomal dominant or sporadic congenital SMA-LED is characterized by nonprogressive congenital or early-onset lower limb–predominant weakness and wasting, and mutations in DYNC1H1 are a common cause of this disease. Mutations located in the tail domain of DYNC1H1 are mostly associated with SMA-LED8,13 or a Charcot-Marie-Tooth phenotype with proximal weakness,10 while mutations in the motor domain have previously only been identified in patients with cognitive impairment but no motor neuron disease.12,13 More recently, MCDs have been documented in 8 individuals carrying DYNC1H1 mutations, 2 of which were located in the tail domain. Of note, 3 subjects from that study had...
clinical features evocative of a neuropathy, although no detailed clinical or electrophysiologic information was provided. Two additional unrelated cases with novel DYNC1H1 mutations, located in the neck and motor domains, respectively, have been described in association with an SMA-LED phenotype and brain cortical malformation. In this study, we report a large cohort of children and adults affected by SMA-LED due to DYNC1H1 mutations, expanding the clinical spectrum to include severe cases with generalized arthrogryposis and milder cases with onset in adulthood. The detection of cognitive/behavioral impairment and cortical malformations in a proportion of affected individuals demonstrates the frequent co-occurrence of central and peripheral pathology. As in the earlier studies, a significant proportion of our subjects had clinically apparent symptom onset at birth or within the first years of life (63%); in about one-quarter of cases (7/30), onset was in adulthood. However, some patients in our case series were so severely affected that they never walked, and also had evidence of congenital involvement of the upper limbs and hands, expanding the spectrum of SMA-LED to encompass generalized neurogenic arthrogryposis. All the remaining subjects remained ambulant, confirming the stable course of the disease. Our cases showed pronounced involvement of the lower limbs in comparison to the upper limbs confirming previous reports but now adding that the upper extremities can be involved in severe cases.

Despite the clinical appearance of distal muscle wasting and foot deformities, the proximal muscles, especially the hip extensors, were the weakest. This is in contrast to the distal weakness reported in dominant SMA families with TRPV4 mutations, suggesting this is a key clinical aspect in the differential diagnosis. Joint contractures were not a predominant clinical feature of the original DYNC1H1 families, but were noted in almost half of our cohort (46.4%). In many cases, contractures were a presenting feature, were found almost exclusively in the lower limbs, and did not progress with time. In the most severe cases, the severity of
the hips, knees, and ankles contractures contributed with the weakness to compromise the ability to walk.

Because the diagnosis was not obvious at presentation, several subjects underwent muscle biopsy. The histopathology showed variable features ranging from classic neurogenic features of fiber-type grouping and fascicular hypertrophy and atrophy, to type 1 or type 2 predominance with or without fiber atrophy as previously reported in molecularly unconfirmed SMA-LED kindreds. Excessive connective tissue was also present in several cases, a feature not seen in typical 5q-SMA. Of note, in a few cases, the predominance of slow fibers and the presence of “core-like” areas originally suggested a congenital myopathy. However, the presence of target fibers is a well-recognized feature in re-innervated muscle as well as a variety of other lesions, including moth-eaten fibers, mini-cores, larger cores, and even vacuolation. Such cases demonstrate the importance of considering clinical, electrophysiologic, and radiologic correlation with the biopsy findings.

The muscle MRI of the lower limbs showed a striking pattern in all patients who had this test, appearing to be highly suggestive of this condition. At the thigh level, there was selective sparing and relative hypertrophy of the adductor compartment and of the semitendinosus muscles. Before the identification of mutations in DYNCIH1 in SMA-LED, we described this imaging pattern in a cohort of 11 patients with genetically unclassified dominant congenital SMA with predominant involvement of the lower limbs. It is of interest that this imaging pattern is different from that described in another form of congenital

Figure 4  Brain imaging

Brain MRI at the age of 3 years in case UK2.I shows a polymicrogyric pattern of frontal lobe cortex (A, B), sylvian fissure extending to the parietal lobe especially on the right side (C), and thin corpus callosum (D). Brain MRI at the age of 2 years in case UK3.I shows immature white matter, polymicrogyria-like pattern of sylvian and frontal cortex (A, B), posterior extension of sylvian fissure (C), and mild cerebellar hypoplasia (D). Brain MRI at the age of 4 years in case UK3.II shows a polymicrogyric pattern of the right frontal lobe (A, B), thin corpus callosum (C), and gyral overconvolution with posterior extension of the right sylvian fissure (D). All these subjects had underdeveloped white matter with thinning of the corpus callosum.
SMA due to mutations in TRPV4, but is very similar to the pattern we recently described in association with mutations in BICD2 encoding a key adaptor protein that interacts with the dynein-dynactin motor complex leading to a combination of SMA-LED and upper motor neuron features. The consistent pattern of muscle imaging in our cohort suggests that the muscle MRI together with the clinical findings is a valuable tool to facilitate appropriate molecular analyses.

In one-third of patients, we detected mild to moderate cognitive impairment and/or behavioral comorbidities consistent with ADHD traits. The prevalence of ADHD in our cohort is higher than that described in the general population and did not appear to be related to the severity of the motor impairment. Of note, cognitive involvement and ADHD are not features we have observed in similarly impaired patients affected by BICD2 mutations (personal observation of the authors). It has previously been reported that mutations in the motor domain of DYNC1H1 can cause severe intellectual disability associated with neuronal migration defects while only 2 cases have been described with learning difficulties associated with Charcot-Marie-Tooth disease type 2 due to a mutation in the tail domain of DYNC1H1. In our cohort, 9 of the 10 patients with cognitive impairment and/or behavioral comorbidities underwent brain MRI, which showed in 4 cases a pattern of cortical malformation. This is in keeping with recent reports that mutations in DYNC1H1 are a common cause of malformations of cortical development (apparently in isolation). Our cases not only indicate that there is often coexistence of central and peripheral pathology, but furthermore showed novel features such as an extended parietal cleft with posterior extension of the sylvian fissure and mild cerebellar hypoplasia.

Our findings confirm that heterozygous missense DYNC1H1 mutations can lead to a wide range of neuronal migration defects in association with a variable degree of cognitive/behavioral impairment. The Loa mice with a Phe580Tyr point mutation in the tail domain of DYNC1H1 show abnormalities of cortical and hippocampal development attributed to impaired radial migration and a reduction in axonal outgrowth. It is likely that the missense mutations identified in this study act in a similar way to the Loa mutation and impair cortical radial migration and lumbar motor neuron axonal outgrowth giving rise to the combined phenotype of SMA-LED and malformation of cortical development.

No clear genotype/phenotype correlations were found in relation to age at onset and severity, but in all cases the conditions remained essentially stable over time.

Our study provides additional information on the inheritance pattern of SMA-LED due to mutations in the tail and motor domains of DYNC1H1. We have reported both de novo mutations and for the first time a codominant homozygous mutation associated with a severe phenotype. We have also expanded the clinical spectrum, both regarding the range of severity to include generalized arthrogryposis and the age at onset, and provided further information on the long-term functional outcome. Furthermore, we confirm a characteristic pattern of muscle involvement both clinically and by MRI, which is useful diagnostically.

AUTHOR CONTRIBUTIONS

M. Scoot: oversaw the design of the study, wrote the first draft of the manuscript, contributed to data collection and to the analysis and interpretation of data. A.M. Rossor: oversaw the design of the study, contributed to the writing of the manuscript, contributed to data collection and to the analysis and interpretation of data, and gave final approval of the version to be published. M.B. Harms: oversaw the design of the study, contributed to the writing of the manuscript, contributed to data collection and to the analysis and interpretation of data, and gave final approval of the version to be published. M. Calissano: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. S. Robb: contributed to revising the manuscript and gave final approval of the version to be published. A. Yang: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. M. De Viss: contributed to data collection, contributed to revising the manuscript and gave final approval of the version to be published. J. Nixon: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. A. Foley: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. M. Benatar: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. A.M. Connolly: contributed to revising the manuscript and gave final approval of the version to be published. M. Manzur: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. C. Sewry: contributed to the analysis and interpretation of data, and gave final approval of the version to be published. I. Hadjikoumi: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. S. Cirak: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. M. Scoto: oversaw the design of the study, wrote the first draft of the manuscript, contributed to data collection and to the analysis and interpretation of data, and gave final approval of the version to be published. M. Taylor: contributed to revising the manuscript, and gave final approval of the version to be published. M. Calissano: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. A. Yang: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. M. De Viss: contributed to data collection, contributed to revising the manuscript and gave final approval of the version to be published. J. Nixon: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. A. Foley: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. M. Benatar: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. A.M. Connolly: contributed to revising the manuscript and gave final approval of the version to be published. M. Manzur: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. C. Sewry: contributed to the analysis and interpretation of data, and gave final approval of the version to be published. I. Hadjikoumi: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. S. Cirak: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. M. Scoto: oversaw the design of the study, wrote the first draft of the manuscript, contributed to data collection and to the analysis and interpretation of data, and gave final approval of the version to be published. M. Benatar: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. A.M. Connolly: contributed to revising the manuscript and gave final approval of the version to be published. M. Manzur: contributed to data collection, contributed to revising the manuscript, and gave final approval of the version to be published. C. Sewry: contributed to the analysis and interpretation of data, and gave final approval of the version to be published.
manuscript, and gave final approval of the version to be published. M. Hafezparast: contributed to revising the manuscript and gave final approval of the version to be published. W.K. Chong: contributed to the analysis and interpretation of data, contributed to revising the manuscript, and gave final approval of the version to be published. E. Mercuri: contributed to the analysis and interpretation of data, contributed to revising the manuscript, and gave final approval of the version to be published. R.H. Baloh: contributed to revising the manuscript and gave final approval of the version to be published. M.M. Reilly: oversaw the design of the study, contributed to the analysis and interpretation of data, contributed to revising the manuscript, and gave final approval of the version to be published. F. Muntoni: oversaw the design of the study, contributed to data collection and to the analysis and interpretation of data, contributed to revising the manuscript, and gave final approval of the version to be published.

ACKNOWLEDGMENT
Data generated by the UK10K Consortium for one family were included in this study. A full list of the investigators who contributed data is available online at Neurology.org. Thalia Antoniadi and Sarah Burton-Jones from the Bristol Genetics Laboratory, North Bristol NHS Trust, Southmead Hospital Bristol, UK, are gratefully acknowledged for the diagnostic work on the molecular genetic confirmation in 2 families. The authors are grateful to the patients who took part in this study and their families.

STUDY FUNDING
Matthew Harms is grateful for support from the NIH/National Institute of Neurological Disorders and Stroke (K08-NS075094) and U11 RR024992 from the National Center for Research Resources (NCRR), a component of the NIH, and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Francesco Muntoni is funded by Great Ormond Street Hospital (GOSH) Children’s Charity and the GOSH Biomedical Research Center, and gratefully acknowledges the MRC Center (G0601943) and the Muscular Dystrophy Campaign Centre grants. Mary M. Reilly is grateful to the Medical Research Council (MRC), MRC Center grant (G0601943), and the National Institutes of Neurological Diseases and Stroke and Office of Rare Diseases (U54NS065712) for their support. Part of this work was undertaken at University College London Hospitals/University College London, which received a proportion of funding from the Department of Health’s National Institute for Health Research Biomedical Research Centers funding scheme. The Neuromuscular MRC Center Biobank is also gratefully acknowledged. Alexander M. Rossor is grateful for his fellowship funding from the National Institutes of Neurological Diseases and Stroke and Office of Rare Diseases (U54NS065712). He has also been in receipt of an IPSEN clinical research fellowship. Funding for UK10K was provided by the Wellcome Trust under award WT091310.

DISCLOSURE
M. Scoto and A. Rossor report no disclosures relevant to the manuscript. M. Harms has received honoraria from Genetech for speaking, grants from the National Institute of Neurological Disorders and Stroke, Ultra-genyx Pharmaceuticals, and Biogen Idec, and nonfinancial research support from ISIS Pharmaceuticals and Oxford Nanopore, all for efforts unrelated to the present study. S. Cirak, M. Calissano, S. Robb, A. Manzur, A. Martínez Arroyo, A. Rodriguez Sanz, S. Mansour, P. Fallon, I. Hadjikoumi, A. Klein, M. Yang, M. De Visser, W. Overweg-Plandsoen, F. Baas, J. Taylor, M. Benatar, A. Connolly, M. Al-Lou, J. Nixon, C. de Goede, A. Foley, C. Mewilliam, M. Pitt, C. Sewry, R. Phadke, M. Hafezparast, W. Chong, E. Mercuri, and R. Baloh report no disclosures relevant to the manuscript. M. Reilly serves on the editorial boards of *Neuromuscular Disorders, Journal of Neurology, Neuromyology and Psychiatry*, and the *Journal of the Peripheral Nervous System* and the editorial advisory board of *Brain*. F. Muntoni serves on scientific advisory boards for Pfizer and has served in the past for Roche, PTC, Summit, Italfarmaco, and RarePath Therapeutics; he serves on the editorial board of *Neuromuscular Disorders and Neuropediatrics*; his institution (UCL) receives research support from the European Union, the Medical Research Council, the Wellcome Trust, the Association Française contre les Myopathies (AFM), the Muscular Dystrophy Campaign, the Great Ormond Street Hospital (GOSH) Biomedical Research Centre, GSK, Genethon, and NIH. His institutions (UCL and GOSH) receive funding for clinical trials from GSK, Trophos, Prosensa, the British Heart Foundation, Summit, and has received funding for trials from AVI BioPharma and PTC Therapeutics. Go to Neurology.org for full disclosures.

Received July 18, 2014. Accepted in final form October 21, 2014.

REFERENCES